AGTC Announces Financial Results And Business Update For The Quarter Ended December 31, 2016

Published: Feb 09, 2017

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2016.

“This year our focus continues to be advancing patient enrollment in the ongoing Phase 1/2 clinical trials for our XLRS and ACHM product candidates and filing the IND for our XLRP product candidate,” said Sue Washer, President and CEO of AGTC. “We are also pursuing additional approaches to leveraging the power of our AAV-based gene delivery technology to improve patients’ lives with many ongoing pre-clinical projects. We are excited about the collaboration we established last month with Bionic Sight, which is expected to provide AGTC and Bionic Sight with a leadership position in the emerging field of optogenetics.”

Back to news